Global Cancer Cases to Grow by 30 Per Cent
2 September 2009
The number of new cancer cases globally will grow by 30% over the next decade, according to a new report from the Economist Intelligence Unit (EIU). By 2020, the number of cases will reach nearly 17 million, an increase of four million on today’s figures. An aging population and the growing prevalence of the disease in the emerging territories are two of the main drivers for the predicted rise. Cancer is already the world’s second biggest killer, claiming more people every year than HIV/AIDS, malaria and tuberculosis combined.
EIU estimates that, with regard to cancer, the price of medical and non-medical costs and lost productivity will total US$286bn in 2009 (an estimation it describes as “conservative”); despite this, only $19bn will be spent on cancer research. The report speculates how much it would cost to achieve a “global funding expenditure standard”, based on achieving per-case spending around the world . It is estimated that achieving this standard, based on 2009 new cancer cases, would require an additional US$217bn.
Commissioned by LIVESTRONG, an initiative of the Lance Armstrong Foundation (LAF), the report, Breakaway: The global burden of cancer - challenges and opportunities, is available free of charge at www.eiu.com/LAF
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
Pfizer, GSK Gain ACIP Recommendations for RSV and Meningococcal Vaccines
April 18th 2025The Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices voted to expand access to Pfizer’s respiratory syncytial virus vaccine Abrysvo for high-risk adults in their 50s and voted in favor of GSK’s meningococcal vaccine, Penmenvy, for streamlined adolescent protection.
